Sutimlimab
(Anti-human C1s mAb, human IgG4-Kappa; BIVV009)
Catalog No.: PC-Ab1041Not For Human Use, Lab Use Only.
Sutimlimab (BIVV009, TNT-009) is a humanized mAb that specifically inhibits the complement (CP)-specific serine protease C1s to evaluate the impact of upstream CP antagonism on activation and proliferation of normal and autoimmune human B cells. Sutimlimab potentially reduce RBC lysis, significantly inhibited complement-mediated activation and proliferation of primary human B cells. antagonism suppressed human Ig-induced activation of B cells derived from patients with rheumatoid arthritis..
Sutimlimab (BIVV009, TNT-009) is a humanized mAb that specifically inhibits the complement (CP)-specific serine protease C1s to evaluate the impact of upstream CP antagonism on activation and proliferation of normal and autoimmune human B cells. Sutimlimab potentially reduce RBC lysis, significantly inhibited complement-mediated activation and proliferation of primary human B cells. antagonism suppressed human Ig-induced activation of B cells derived from patients with rheumatoid arthritis.
Physicochemical Properties
M.Wt
Formula
Human IgG4-Kappa
Appearance
Solid
CAS No.
Storage
Solide Powder
-20 °C 12 Months; 4°C 6 Months
In Solvent
-80 °C 6 Months; -20°C 6 Months
Shipping
Solubility
PBS, pH 7.0
Contains no stabilizers or preservatives
